Haemonetics (NYSE:HAE) Announces Earnings Results, Misses Estimates By $0.01 EPS

Haemonetics (NYSE:HAE) released its quarterly earnings results on Thursday. The medical instruments supplier reported $1.19 EPS for the quarter, missing analysts’ consensus estimates of $1.20 by ($0.01), Zacks reports. Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. Haemonetics updated its FY 2025 guidance to 4.500-4.700 EPS.

Haemonetics Stock Performance

Shares of HAE opened at $59.34 on Friday. The company has a quick ratio of 2.09, a current ratio of 3.97 and a debt-to-equity ratio of 1.35. The stock has a market cap of $2.98 billion, a P/E ratio of 23.36, a P/E/G ratio of 0.98 and a beta of 0.39. The business’s 50 day moving average price is $76.38 and its 200-day moving average price is $78.41. Haemonetics has a 52 week low of $59.09 and a 52 week high of $97.97.

Analyst Ratings Changes

A number of brokerages recently commented on HAE. JMP Securities dropped their price target on Haemonetics from $125.00 to $100.00 and set a “market outperform” rating for the company in a research note on Friday. Barrington Research dropped their target price on shares of Haemonetics from $108.00 to $95.00 and set an “outperform” rating for the company in a research report on Friday. Raymond James reiterated a “strong-buy” rating and set a $115.00 price target (down previously from $120.00) on shares of Haemonetics in a research report on Friday. JPMorgan Chase & Co. started coverage on shares of Haemonetics in a report on Friday, December 6th. They issued an “overweight” rating and a $116.00 price objective for the company. Finally, Bank of America downgraded Haemonetics from a “neutral” rating to an “underperform” rating and reduced their target price for the stock from $95.00 to $68.00 in a report on Friday. One analyst has rated the stock with a sell rating, one has issued a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Haemonetics has a consensus rating of “Moderate Buy” and an average price target of $101.67.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.